US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palvella Therapeutics

25.40

+1.918.13%

Post-market: 25.400.00000.00%17:24 EDT

Volume:48.49K

Turnover:1.21M

Market Cap:280.81M

PE:-5.03

High:25.88

Open:24.10

Low:23.52

Close:23.49

Loading ...

Overview Company News Filings

Palvella Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Ashley Kline

Palvella Therapeutics Advances in Rare Skin Disease Therapies

Palvella Therapeutics Strengthens Executive Leadership Team With Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

THOMSON REUTERS

Press Release: Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

Palvella Therapeutics Is Maintained at Buy by Canaccord Genuity

Scotiabank Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)

Palvella Therapeutics price target lowered to $52 from $53 at Canaccord

Chardan Capital Sticks to Their Buy Rating for Palvella Therapeutics (PVLA)

Palvella Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Palvella Therapeutics Q1 EPS $(0.74) Beats $(1.44) Estimate

Palvella Therapeutics Inc - Phase 2 Toiva Trial Results Expected Q4 2025

THOMSON REUTERS

Palvella Therapeutics Inc expected to post a loss of $1.21 a share - Earnings Preview

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.

Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics

One Palvella Therapeutics Insider Raised Their Stake In The Previous Year

Simply Wall St.

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Palvella Says US Patent Granted for Qtorin Gel to Treat Rare Skin Disorder

MT Newswires Live

Palvella Therapeutics granted U.S patent for QTORIN Rapamycin

Palvella Therapeutics Granted Additional U.S. Patent for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PVLA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":25.4,"timestamp":1749240000000,"preClose":23.49,"halted":0,"volume":48489,"hourTrading":{"tag":"盘后","latestPrice":25.4,"preClose":25.4,"latestTime":"17:24 EDT","volume":120,"amount":3047.51,"timestamp":1749245066126},"delay":0,"floatShares":5730612,"shares":11055665,"eps":-5.045167,"marketStatus":"Market Closed","change":1.91,"latestTime":"06-06 16:00:00 EDT","open":24.1,"high":25.88,"low":23.52,"amount":1210678.68579,"amplitude":0.100468,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.045167,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":23.49,"preHourTrading":{"tag":"盘前","latestPrice":23.49,"preClose":23.49,"latestTime":"08:26 EDT","volume":20,"amount":469.79999999999995,"timestamp":1749212800674},"postHourTrading":{"tag":"盘后","latestPrice":25.4,"preClose":25.4,"latestTime":"17:24 EDT","volume":120,"amount":3047.51,"timestamp":1749245066126},"volumeRatio":0.5341563034301509,"impliedVol":0.4412,"impliedVolPercentile":0.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":5730612,"roa":"-18.39%","roe":"-89.30%","lyrEps":-7.832217,"volumeRatio":0.5341563034301509,"shares":11055665,"dividePrice":0,"high":25.88,"amplitude":0.100468,"preClose":23.49,"low":23.52,"week52Low":6.2,"pbRate":"5.05","week52High":29.27,"institutionHeld":0,"latestPrice":25.4,"eps":-5.045167,"divideRate":0,"volume":48489,"delay":0,"ttmEps":-5.045167,"open":24.1,"prevYearClose":12,"prevWeekClose":24.13,"prevMonthClose":24.13,"prevQuarterClose":27.99,"fiveDayClose":24.13,"twentyDayClose":23.04,"sixtyDayClose":29},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540086412","title":"Palvella Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Ashley Kline","url":"https://stock-news.laohu8.com/highlight/detail?id=2540086412","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540086412?lang=en_us&edition=fundamental","pubTime":"2025-06-04 09:08","pubTimestamp":1748999336,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc. has filed an initial statement of beneficial ownership. The filing identifies Ashley Hartmann Kline as the beneficial owner, serving in the role of Chief Commercial Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL6H755C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2539108202","title":"Palvella Therapeutics Advances in Rare Skin Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2539108202","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539108202?lang=en_us&edition=fundamental","pubTime":"2025-05-31 11:55","pubTimestamp":1748663732,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, Inc. ( ($PVLA) ) has released its Q1 earnings. Here is a breakdown of the information Palvella Therapeutics, Inc. presented ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-advances-in-rare-skin-disease-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-advances-in-rare-skin-disease-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2538465753","title":"Palvella Therapeutics Strengthens Executive Leadership Team With Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2538465753","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538465753?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:00","pubTimestamp":1748347202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA3DDGCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2538784465","title":"Press Release: Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2538784465","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538784465?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:00","pubTimestamp":1748347200,"startTime":"0","endTime":"0","summary":"Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN 3.9% rapamycin anhydrous gel  for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved. Under Kline's leadership at Dompé, Oxervate, a first-in-disease topical therapy for rare disease neurotrophic keratitis, scaled to over $500 million in annual U.S. sales while achieving early profitability. Earlier in her career, Ms. Kline was a member of the commercial team at Genentech and a consultant for Bain and Company. She also held commercial roles at Santen Pharmaceuticals and Adverum Biotech. Ms. Kline earned her M.B.A. from the Kellogg School of Management at Northwestern University with majors in Finance, Decision Science, and Analytical Consulting and a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","BK4585","TM","PVLA","R","03160","BK4099","BK4555","BK4588","TISI","BK4232","BK4604","BK4022","BK4139"],"gpt_icon":0},{"id":"2535892390","title":"Palvella Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2535892390","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535892390?lang=en_us&edition=fundamental","pubTime":"2025-05-16 20:58","pubTimestamp":1747400280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2025 08:58 ET (12:58 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2535396312","title":"Scotiabank Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535396312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535396312?lang=en_us&edition=fundamental","pubTime":"2025-05-16 19:16","pubTimestamp":1747394197,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Louise Chen maintained a Buy rating on Palvella Therapeutics (PVLA – Research Report) today and set a price target of $50.00. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/scotiabank-sticks-to-its-buy-rating-for-palvella-therapeutics-pvla-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/scotiabank-sticks-to-its-buy-rating-for-palvella-therapeutics-pvla-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2535639844","title":"Palvella Therapeutics price target lowered to $52 from $53 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2535639844","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535639844?lang=en_us&edition=fundamental","pubTime":"2025-05-16 18:40","pubTimestamp":1747392011,"startTime":"0","endTime":"0","summary":"Canaccord analyst Whitney Ijem lowered the firm’s price target on Palvella Therapeutics (PVLA) to $52 from $53 and keeps a Buy rating on the shares...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-lowered-to-52-from-53-at-canaccord?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-lowered-to-52-from-53-at-canaccord?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2535580385","title":"Chardan Capital Sticks to Their Buy Rating for Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535580385","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535580385?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:35","pubTimestamp":1747341306,"startTime":"0","endTime":"0","summary":"In a report released today, Geulah Livshits from Chardan Capital maintained a Buy rating on Palvella Therapeutics (PVLA – Research Report), with a ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-palvella-therapeutics-pvla?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-palvella-therapeutics-pvla?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2535826349","title":"Palvella Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535826349","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535826349?lang=en_us&edition=fundamental","pubTime":"2025-05-15 21:38","pubTimestamp":1747316305,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryPalvella Therapeutics Inc PVLA.OQ reported a quarterly adjusted loss of 74 cents per share for the quarter en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nL8N3RN1P0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2535849064","title":"Palvella Therapeutics Q1 EPS $(0.74) Beats $(1.44) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535849064","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535849064?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:31","pubTimestamp":1747308706,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(1.44) by 48.61 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45433437/palvella-therapeutics-q1-eps-0-74-beats-1-44-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2535849008","title":"Palvella Therapeutics Inc - Phase 2 Toiva Trial Results Expected Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2535849008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535849008?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:30","pubTimestamp":1747308601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUA6WXFL4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2535570838","title":"Palvella Therapeutics Inc  expected to post a loss of $1.21 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2535570838","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535570838?lang=en_us&edition=fundamental","pubTime":"2025-05-13 22:45","pubTimestamp":1747147504,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc  expected to post a loss of $1.21 a share - Earnings Preview Palvella Therapeutics Inc PVLA.OQ PVLA.O is expected to report resultson May 15 for the period ending March 31 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nL8N3RL1Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Palvella Therapeutics Inc  expected to post a loss of $1.21 a share - Earnings Preview","news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2533825585","title":"Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2533825585","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533825585?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:30","pubTimestamp":1746444600,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., May 05, 2025  --  Palvella Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration -approved therapies, announced today that the Company will ring the opening bell at the Nasdaq Stock Market  on Monday, May 12, 2025 in New York City.Wes Kaupinen, Founder and Chief Executive Officer, will be joined by members of the Palvella management team, Board of Directors, investors, advisors, and guests at the ceremony which will begin at approximately 9:15 am ET.“We are honored to have been invited by Nasdaq to participate in the opening bell ceremony and highlight Palvella’s vision to build the leading rare disease biopharmaceutical company serving individuals afflicted with serious, rare genetic skin diseases,” said Mr. Kaupinen. “Becoming a publicly traded, Nasdaq-listed company is a major cor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palvella-therapeutics-ring-nasdaq-opening-113000351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","TSYW.SI","BK4213","USJW.SI","IE00BGHQF748.EUR","QID","LU2095319765.USD","SQQQ","BK4588","QLD","TQQQ","PVLA","MNQmain","IE00BKPKM429.USD","BK4139","BK4112","BK4585","LU2210150020.SGD","USAW.SI","REI","IE00B64PRP62.GBP","NQmain","IE00B3QW5Z07.USD","NDAQ",".IXIC","PSQ","LU2210149790.SGD"],"gpt_icon":1},{"id":"2531873038","title":"Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2531873038","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531873038?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2025 07:00 ET (11:00 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2531823950","title":"Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2531823950","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531823950?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:16","pubTimestamp":1746008195,"startTime":"0","endTime":"0","summary":"Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Palvella Therapeutics (PVLA – Research Report). The associated price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-potential-of-qtorin-in-addressing-unmet-needs-in-vascular-anomalies-a-buy-recommendation-for-palvella-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-potential-of-qtorin-in-addressing-unmet-needs-in-vascular-anomalies-a-buy-recommendation-for-palvella-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2530226961","title":"One Palvella Therapeutics Insider Raised Their Stake In The Previous Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2530226961","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530226961?lang=en_us&edition=fundamental","pubTime":"2025-04-26 22:28","pubTimestamp":1745677685,"startTime":"0","endTime":"0","summary":"Insiders were net buyers of Palvella Therapeutics, Inc.'s  stock during the past year. That is, insiders bought more stock than they sold.Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.Palvella Therapeutics Insider Transactions Over The Last Year. In the last twelve months, the biggest single purchase by an insider was when Independent Chairman of the Board George Jenkins bought US$52k worth of shares at a price of US$12.93 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$25.39. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's pric","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/one-palvella-therapeutics-insider-raised-142805102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2529101668","title":"Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2529101668","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529101668?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:15","pubTimestamp":1745439300,"startTime":"0","endTime":"0","summary":"Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations  with cutaneous involvement. Estimates of annual incidence of LMs with cutaneous involvement to be highlighted in the poster presentation. WAYNE, Pa., April 23, 2025  --  Palvella Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration -approved therapies, today announced an abstract highlighting the estimated diagnosed prevalence and annual incidence of lymphatic malformation  cases in the U.S. was accepted for poster presentation at the Society for Investigative Dermatology  Annual Meeting, taking placeMay 7-10, 2025, inSan Diego, California.“This study is the first to quantify the U.S. LM population based on a rigorous, quantitative analysis of medical claims data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palvella-therapeutics-announces-abstract-highlighting-201500649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PVLA","SID","BK4006","BK4139"],"gpt_icon":0},{"id":"2529587195","title":"Palvella Says US Patent Granted for Qtorin Gel to Treat Rare Skin Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2529587195","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529587195?lang=en_us&edition=fundamental","pubTime":"2025-04-22 22:23","pubTimestamp":1745331790,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) said Tuesday the US Patent and Trademark Office has granted a fifth patent for its product candidate Qtorin 3.9% rapamycin anhydrous gel in treating microcystic lymphatic ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2529370130","title":"Palvella Therapeutics granted U.S patent for QTORIN Rapamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2529370130","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529370130?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:37","pubTimestamp":1745321876,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced that the United States Patent and Trademark Office, USPTO, issued patent No. 12,268,673 for claims related t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-granted-u-s-patent-for-qtorin-rapamycin?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-granted-u-s-patent-for-qtorin-rapamycin?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2529779103","title":"Palvella Therapeutics Granted Additional U.S. Patent for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2529779103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529779103?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:30","pubTimestamp":1745321400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUACBHYHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":77,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"PVLA","fiscalQuarterEnding":"2025/03","expectedEps":-3.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.74},{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19},{"market":"US","date":"2024-08-14","symbol":"PVLA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-2.76},{"market":"US","date":"2024-05-15","symbol":"PVLA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-3.95}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.8889,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8889,"analysts":9,"updateTime":1744257600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2025-06-06","current":-11.250599,"percent":0.333333,"low":-17.690417,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"high":46.119317,"avg":11.420347,"sd":22.084191,"marketCap":259697570},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570}],"updateTime":1749375407665}}}